Robeco Institutional Asset Management B.V. grew its holdings in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) by 820.6% during the 2nd quarter, according to the company in its most recent filing with the SEC. The fund owned 9,850 shares of the biopharmaceutical company’s stock after purchasing an additional 8,780 shares during the period. Robeco Institutional Asset Management B.V.’s holdings in Alexion Pharmaceuticals were worth $1,198,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. Morgan Stanley increased its stake in shares of Alexion Pharmaceuticals by 112.0% in the 1st quarter. Morgan Stanley now owns 585,482 shares of the biopharmaceutical company’s stock valued at $70,983,000 after purchasing an additional 309,299 shares during the last quarter. Baird Financial Group Inc. increased its stake in shares of Alexion Pharmaceuticals by 219.0% in the 1st quarter. Baird Financial Group Inc. now owns 14,606 shares of the biopharmaceutical company’s stock valued at $1,771,000 after purchasing an additional 10,028 shares during the last quarter. LS Investment Advisors LLC increased its stake in shares of Alexion Pharmaceuticals by 13.0% in the 1st quarter. LS Investment Advisors LLC now owns 6,131 shares of the biopharmaceutical company’s stock valued at $743,000 after purchasing an additional 706 shares during the last quarter. LMR Partners LLP bought a new position in shares of Alexion Pharmaceuticals in the 1st quarter valued at $927,000. Finally, Morse Asset Management Inc bought a new position in shares of Alexion Pharmaceuticals in the 1st quarter valued at $1,508,000. Institutional investors own 94.26% of the company’s stock.

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) opened at 145.12 on Thursday. The firm has a market capitalization of $32.39 billion, a P/E ratio of 62.93 and a beta of 1.40. The stock has a 50 day moving average price of $136.10 and a 200-day moving average price of $123.99. Alexion Pharmaceuticals, Inc. has a 52 week low of $96.18 and a 52 week high of $149.34.

Alexion Pharmaceuticals (NASDAQ:ALXN) last posted its quarterly earnings data on Thursday, July 27th. The biopharmaceutical company reported $1.56 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.08 by $0.48. The business had revenue of $912 million for the quarter, compared to analysts’ expectations of $846.15 million. Alexion Pharmaceuticals had a return on equity of 12.47% and a net margin of 15.31%. The business’s revenue was up 21.1% on a year-over-year basis. During the same period in the previous year, the firm posted $1.13 EPS. Analysts anticipate that Alexion Pharmaceuticals, Inc. will post $5.60 EPS for the current fiscal year.

A number of equities research analysts recently weighed in on the company. Stifel Nicolaus restated a “buy” rating and set a $157.00 price objective on shares of Alexion Pharmaceuticals in a research report on Wednesday, May 24th. Jefferies Group LLC set a $120.00 price objective on Alexion Pharmaceuticals and gave the stock a “hold” rating in a research report on Thursday, June 8th. UBS AG restated a “buy” rating and set a $140.00 price objective (down previously from $143.00) on shares of Alexion Pharmaceuticals in a research report on Wednesday, May 31st. J P Morgan Chase & Co restated a “hold” rating on shares of Alexion Pharmaceuticals in a research report on Wednesday, June 14th. Finally, BidaskClub upgraded Alexion Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, June 20th. Five investment analysts have rated the stock with a hold rating, twenty have given a buy rating and three have issued a strong buy rating to the stock. The stock currently has an average rating of “Buy” and an average price target of $156.32.

ILLEGAL ACTIVITY NOTICE: “Alexion Pharmaceuticals, Inc. (ALXN) Stake Boosted by Robeco Institutional Asset Management B.V.” was originally reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this article on another website, it was copied illegally and republished in violation of U.S. & international trademark & copyright laws. The legal version of this article can be accessed at https://www.thecerbatgem.com/2017/09/07/alexion-pharmaceuticals-inc-alxn-stake-boosted-by-robeco-institutional-asset-management-b-v.html.

In other Alexion Pharmaceuticals news, Director Bros. Advisors Lp Baker bought 1,348,955 shares of the stock in a transaction dated Wednesday, June 14th. The stock was purchased at an average cost of $116.32 per share, for a total transaction of $156,910,445.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Ludwig Hantson bought 10,000 shares of the stock in a transaction dated Wednesday, June 14th. The shares were acquired at an average price of $116.72 per share, with a total value of $1,167,200.00. Following the completion of the acquisition, the chief executive officer now directly owns 38,725 shares of the company’s stock, valued at approximately $4,519,982. The disclosure for this purchase can be found here. Over the last ninety days, insiders have acquired 2,019,734 shares of company stock worth $235,606,846 and have sold 17,070 shares worth $2,416,869. Insiders own 4.35% of the company’s stock.

About Alexion Pharmaceuticals

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).

Institutional Ownership by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Stock Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.